Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
Authors' conclusion
Increased HOMA-B and improved metabolic biomarkers suggest that treatment with the orally administered non-peptide GLP-1 receptor agonist orforglipron enhanced pancreatic β-cell function and insulin sensitivity in patients with T2D.
Study context
- Population
- Adults with inadequately controlled T2D
- Participants
- 378 adults
- Comparison
- Orforglipron vs dulaglutide and placebo
Methodological detailsparticipant-level exploratory analyses, 26-week
- Participant-level exploratory analyses
- 26-week
Primary result
As reported in the abstract
26 weeks
HOMA-B increase with orforglipron ≥12 mg from baseline to week 4 before stabilising (C-peptide)
up to 123%
HOMA-B increase with orforglipron ≥12 mg from baseline to week 4 before stabilising (insulin)
up to 132%
HOMA-IR decrease with orforglipron by week 26 (C-peptide)
up to 16%
HOMA-IR decrease with orforglipron by week 26 (insulin)
up to 23%
Original publication
Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes. Diabetes Obes Metab. Published 14 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →